UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

Diabetes, obesity & metabolism, 2014-05, Vol.16 (5), p.467-477

2014

Volltextzugriff (PDF)

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2015-04, Vol.17 (4), p.426-429

2015

Volltextzugriff (PDF)

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia

Journal of psychopharmacology (Oxford), 2011-05, Vol.25 (5), p.685-697

2011

Volltextzugriff (PDF)

Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control

Journal of neurology, 2004-08, Vol.251 (8), p.943-950

2004

Volltextzugriff (PDF)

Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea

Diabetes, obesity & metabolism, 2015-01, Vol.17 (1), p.23-31

2015

Volltextzugriff (PDF)

Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials

Acta neurologica Scandinavica, 2004-10, Vol.110 (4), p.221-231

2004

Volltextzugriff (PDF)

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

The New England journal of medicine, 2019-02, Vol.380 (8), p.720-728

2019

Volltextzugriff (PDF)

PO417 CANAGLIFLOZIN ADDED ON TO ALPHA-GLUCOSIDASE INHIBITORS WITH OR WITHOUT OTHER ANTIHYPERGLYCAEMIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Diabetes research and clinical practice, 2014-11, Vol.106, p.S258-S258

2014

Volltextzugriff (PDF)

Composite quality measure (CQM) attainment in overweight/obese patients with type 2 diabetes mellitus treated with canagliflozin 300 mg (CANA) or sitagliptin 100 mg (SITA)

Value in health, 2014-05, Vol.17 (3), p.A239-A239

2014

Volltextzugriff (PDF)

Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes mellitus

Indian heart journal, 2017-11, Vol.69 (S2), p.S93-S94

2017

Volltextzugriff (PDF)

P336 Efficacité et tolérance de la canagliflozine chez des diabétiques de type 2 (DT2) mal contrôlés par metformine plus sulfamide hypoglycémiant sur une période de 52 semaines

Diabetes & metabolism, 2014-03, Vol.40, p.A107-A107

2014

Volltextzugriff (PDF)

OC-12 D-dimer levels significantly decline in ambulatory cancer patients receiving rivaroxaban compared to placebo: biomarker analysis of the CASSINI trial

Thrombosis research, 2021-04, Vol.200, p.S12

2021

Volltextzugriff (PDF)

Topiramate and physiologic measures of nerve function in polyneuropathy

Acta neurologica Scandinavica, 2007-04, Vol.115 (4), p.222-231

2007

Volltextzugriff (PDF)

P3840Use of oral anticoagulation is less among hospitalized patients with paroxysmal compared to persistent or permanent atrial fibrillation

European heart journal, 2018-08, Vol.39 (suppl_1)

2018

Volltextzugriff (PDF)

PDB11 - Composite quality measure (CQM) attainment in overweight/obese patients with type 2 diabetes mellitus treated with canagliflozin 300 mg (CANA) or sitagliptin 100 mg (SITA)

Value in health, 2014-05, Vol.17 (3), p.A239-A239

2014

Volltextzugriff (PDF)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome

Diabetes, metabolic syndrome and obesity, 2017-01, Vol.10, p.47-55

2017

Volltextzugriff (PDF)

The transcriptome of the leukemogenic homeoprotein HOXA9 in human hematopoietic cells

Blood, 2004-03, Vol.103 (5), p.1676-1684

2004

Volltextzugriff (PDF)

227 POSTER Anti-angiogenic effects of PI3K/Akt/mTOR pathway inhibitors

European journal of cancer supplements, 2008, Vol.6 (12), p.71-71

2008

Volltextzugriff (PDF)

Roles of mitogen-activated protein kinase and phosphoinositide 3′-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling

Experimental cell research, 2003-04, Vol.284 (2), p.289-300

2003

Volltextzugriff (PDF)

Protein Kinase C-Mediated Phosphorylation of the Leukemia-Associated HOXA9 Protein Impairs Its DNA Binding Ability and Induces Myeloid Differentiation

Molecular and Cellular Biology, 2004-05, Vol.24 (9), p.3827-3837

2004

Volltextzugriff (PDF)

Reciprocal signaling between spiral ganglion neurons and Schwann cells involves neuregulin and neurotrophins

Hearing research, 2001-11, Vol.161 (1), p.87-98

2001

Volltextzugriff (PDF)

Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein

Biochemical journal, 1998-08, Vol.334 ( Pt 1) (1), p.189-195

1998

Volltextzugriff (PDF)

P.3.a.041 Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets

European neuropsychopharmacology, 2006, Vol.16, p.S387-S387

2006

Volltextzugriff (PDF)

Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study (PAL-SCH-301)

Pharmacopsychiatry, 2007, Vol.40 (5)

2007

Volltextzugriff (PDF)

Mutation of a Shc Binding Site Tyrosine Residue in ErbB3/HER3 Blocks Heregulin-dependent Activation of Mitogen-activated Protein Kinase

The Journal of biological chemistry, 1998-08, Vol.273 (33), p.20996-21002

1998

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(28)
Tagungsberichte
(1)

Sprache

Englisch
(28)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia

Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control

Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea

Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

PO417 CANAGLIFLOZIN ADDED ON TO ALPHA-GLUCOSIDASE INHIBITORS WITH OR WITHOUT OTHER ANTIHYPERGLYCAEMIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Composite quality measure (CQM) attainment in overweight/obese patients with type 2 diabetes mellitus treated with canagliflozin 300 mg (CANA) or sitagliptin 100 mg (SITA)

Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes mellitus

P336 Efficacité et tolérance de la canagliflozine chez des diabétiques de type 2 (DT2) mal contrôlés par metformine plus sulfamide hypoglycémiant sur une période de 52 semaines

OC-12 D-dimer levels significantly decline in ambulatory cancer patients receiving rivaroxaban compared to placebo: biomarker analysis of the CASSINI trial

Topiramate and physiologic measures of nerve function in polyneuropathy

P3840Use of oral anticoagulation is less among hospitalized patients with paroxysmal compared to persistent or permanent atrial fibrillation

PDB11 - Composite quality measure (CQM) attainment in overweight/obese patients with type 2 diabetes mellitus treated with canagliflozin 300 mg (CANA) or sitagliptin 100 mg (SITA)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome

The transcriptome of the leukemogenic homeoprotein HOXA9 in human hematopoietic cells

227 POSTER Anti-angiogenic effects of PI3K/Akt/mTOR pathway inhibitors

Roles of mitogen-activated protein kinase and phosphoinositide 3′-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling

Protein Kinase C-Mediated Phosphorylation of the Leukemia-Associated HOXA9 Protein Impairs Its DNA Binding Ability and Induces Myeloid Differentiation

Reciprocal signaling between spiral ganglion neurons and Schwann cells involves neuregulin and neurotrophins

Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein

P.3.a.041 Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets

Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study (PAL-SCH-301)

Mutation of a Shc Binding Site Tyrosine Residue in ErbB3/HER3 Blocks Heregulin-dependent Activation of Mitogen-activated Protein Kinase

Suchergebnisse filtern